Chromocell Therapeutics Corporation (CHRO)
USD 0.59
(-4.76%)
USD 0.59
(-4.76%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -6.86 Million USD | -196.02% |
| 2022 | -1.62 Million USD | -176.3% |
| 2021 | - USD | 38.03% |
| 2020 | - USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | -1.76 Million USD | 8.78% |
| 2024 Q1 | -1.93 Million USD | 50.14% |
| 2023 Q3 | -1.29 Million USD | -66.21% |
| 2023 Q1 | -914.58 Thousand USD | -31.22% |
| 2023 FY | - USD | -196.02% |
| 2023 Q2 | -777.16 Thousand USD | 15.03% |
| 2023 Q4 | -3.87 Million USD | -200.28% |
| 2022 Q4 | -696.98 Thousand USD | -34.33% |
| 2022 FY | - USD | -176.3% |
| 2022 Q3 | -518.83 Thousand USD | -74.89% |
| 2022 Q2 | -296.66 Thousand USD | -3.06% |
| 2022 Q1 | -287.84 Thousand USD | 0.0% |
| 2021 FY | - USD | 38.03% |
| 2020 FY | - USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| AIM ImmunoTech Inc. | -31.67 Million USD | 78.337% |
| Ampio Pharmaceuticals, Inc. | - USD | Infinity% |
| Armata Pharmaceuticals, Inc. | -39.91 Million USD | 82.809% |
| Actinium Pharmaceuticals, Inc. | -51.13 Million USD | 86.579% |
| Azitra, Inc. | -10.67 Million USD | 35.705% |
| Can-Fite BioPharma Ltd. | -8.18 Million USD | 16.109% |
| Calidi Biotherapeutics, Inc. | -28.6 Million USD | 76.006% |
| CEL-SCI Corporation | -27.56 Million USD | 75.101% |
| iBio, Inc. | -14.02 Million USD | 51.057% |
| Lineage Cell Therapeutics, Inc. | -24.73 Million USD | 72.255% |
| MAIA Biotechnology, Inc. | -20.18 Million USD | 65.999% |
| Matinas BioPharma Holdings, Inc. | -22.82 Million USD | 69.935% |
| Navidea Biopharmaceuticals, Inc. | -13.87 Million USD | 50.542% |
| NovaBay Pharmaceuticals, Inc. | -4.8 Million USD | -42.964% |
| NanoViricides, Inc. | -7.75 Million USD | 11.535% |
| Oragenics, Inc. | -20.87 Million USD | 67.131% |
| BiomX Inc. | -22.81 Million USD | 69.922% |
| BiomX Inc. | -22.81 Million USD | 69.922% |
| Protalix BioTherapeutics, Inc. | 11.65 Million USD | 158.899% |
| Palatin Technologies, Inc. | -29.03 Million USD | 76.362% |
| Scorpius Holdings, Inc. | -35.08 Million USD | 80.44% |